UroGen Common Stock Total Equity vs Common Stock Shares Outstanding Analysis
URGN Stock | USD 13.30 0.25 1.85% |
UroGen Pharma financial indicator trend analysis is much more than just breaking down UroGen Pharma prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether UroGen Pharma is a good investment. Please check the relationship between UroGen Pharma Common Stock Total Equity and its Common Stock Shares Outstanding accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UroGen Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.
Common Stock Total Equity vs Common Stock Shares Outstanding
Common Stock Total Equity vs Common Stock Shares Outstanding Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of UroGen Pharma Common Stock Total Equity account and Common Stock Shares Outstanding. At this time, the significance of the direction appears to have almost identical trend.
The correlation between UroGen Pharma's Common Stock Total Equity and Common Stock Shares Outstanding is 0.92. Overlapping area represents the amount of variation of Common Stock Total Equity that can explain the historical movement of Common Stock Shares Outstanding in the same time period over historical financial statements of UroGen Pharma, assuming nothing else is changed. The correlation between historical values of UroGen Pharma's Common Stock Total Equity and Common Stock Shares Outstanding is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Total Equity of UroGen Pharma are associated (or correlated) with its Common Stock Shares Outstanding. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock Shares Outstanding has no effect on the direction of Common Stock Total Equity i.e., UroGen Pharma's Common Stock Total Equity and Common Stock Shares Outstanding go up and down completely randomly.
Correlation Coefficient | 0.92 |
Relationship Direction | Positive |
Relationship Strength | Very Strong |
Common Stock Total Equity
The total value of common stock equity held by shareholders, representing their ownership interest in the company.Common Stock Shares Outstanding
The total number of shares of a company's common stock that are currently owned by all its shareholders.Most indicators from UroGen Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into UroGen Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UroGen Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.At this time, UroGen Pharma's Selling General Administrative is very stable compared to the past year. As of the 1st of June 2024, Tax Provision is likely to grow to about 1.2 M, while Issuance Of Capital Stock is likely to drop about 41.2 M.
2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 17.3M | 1.0M | 1.7M | 3.0M | Interest Income | 365K | 938K | 2.4M | 1.9M |
UroGen Pharma fundamental ratios Correlations
Click cells to compare fundamentals
UroGen Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
UroGen Pharma fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 202.4M | 122.0M | 119.7M | 136.2M | 178.3M | 98.8M | |
Total Current Liabilities | 19.5M | 21.4M | 22.4M | 23.9M | 31.2M | 32.8M | |
Total Stockholder Equity | 180.3M | 96.4M | 8.4M | (88.7M) | (65.2M) | (62.0M) | |
Net Tangible Assets | 180.3M | 96.4M | 8.4M | (89.4M) | (102.8M) | (97.6M) | |
Retained Earnings | (228.0M) | (356.5M) | (467.3M) | (577.1M) | (679.3M) | (645.4M) | |
Accounts Payable | 4.7M | 3.3M | 5.8M | 5.5M | 6.5M | 4.3M | |
Cash | 49.7M | 103.9M | 44.4M | 55.4M | 95.8M | 53.4M | |
Other Current Assets | 1.0M | 3.4M | 7.5M | 11.1M | 10.3M | 10.8M | |
Total Liab | 22.1M | 25.7M | 111.3M | 225.0M | 243.5M | 255.7M | |
Total Current Assets | 148.6M | 115.6M | 114.4M | 128.9M | 169.2M | 90.2M | |
Common Stock | 57K | 60K | 61K | 63K | 89K | 93.5K | |
Property Plant Equipment | 4.7M | 4.2M | 2.0M | 1.3M | 1.5M | 1.7M | |
Common Stock Shares Outstanding | 20.5M | 21.8M | 22.3M | 22.8M | 28.8M | 18.3M | |
Other Current Liab | 14.8M | 15.9M | 12.8M | 16.8M | 19.5M | 10.8M | |
Property Plant And Equipment Net | 4.7M | 4.2M | 3.1M | 3.7M | 2.4M | 2.6M | |
Net Debt | (47.1M) | (102.4M) | (44.0M) | 43.7M | 4.4M | 4.6M | |
Non Current Assets Total | 53.8M | 6.4M | 5.4M | 6.7M | 9.1M | 10.4M | |
Cash And Short Term Investments | 147.1M | 103.9M | 89.8M | 100.0M | 137.8M | 96.8M | |
Common Stock Total Equity | 57K | 60K | 61K | 63K | 72.5K | 45.9K | |
Liabilities And Stockholders Equity | 202.4M | 122.0M | 119.7M | 136.2M | 178.3M | 119.8M | |
Non Current Liabilities Total | 2.6M | 4.2M | 89.0M | 201.1M | 212.3M | 222.9M | |
Capital Surpluse | 408.0M | 452.5M | 475.7M | 487.8M | 561.0M | 307.7M | |
Other Stockholder Equity | 408.0M | 452.5M | 475.7M | 488.4M | 614.0M | 348.8M | |
Property Plant And Equipment Gross | 4.7M | 4.2M | 2.0M | 1.3M | 6.3M | 6.6M | |
Accumulated Other Comprehensive Income | 276K | 271K | (25K) | (107K) | 12K | 12.6K | |
Non Currrent Assets Other | 487K | 289K | 1.5M | 2.7M | 2.0M | 1.1M | |
Other Assets | 487K | 289K | 29.9K | 620K | 713K | 367.9K | |
Net Invested Capital | 180.3M | 96.4M | 8.4M | 8.2M | 33.3M | 55.5M | |
Net Working Capital | 129.2M | 94.2M | 92.0M | 105.0M | 138.0M | 112.3M | |
Retained Earnings Total Equity | (228.0M) | (356.5M) | (467.3M) | (577.1M) | (519.4M) | (545.4M) | |
Capital Stock | 57K | 60K | 61K | 63K | 89K | 68.6K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in UroGen Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.Note that the UroGen Pharma information on this page should be used as a complementary analysis to other UroGen Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Complementary Tools for UroGen Stock analysis
When running UroGen Pharma's price analysis, check to measure UroGen Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy UroGen Pharma is operating at the current time. Most of UroGen Pharma's value examination focuses on studying past and present price action to predict the probability of UroGen Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move UroGen Pharma's price. Additionally, you may evaluate how the addition of UroGen Pharma to your portfolios can decrease your overall portfolio volatility.
Global Correlations Find global opportunities by holding instruments from different markets | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data |
Is UroGen Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UroGen Pharma. If investors know UroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UroGen Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.22) | Revenue Per Share 2.688 | Quarterly Revenue Growth 0.092 | Return On Assets (0.28) | Return On Equity (14.81) |
The market value of UroGen Pharma is measured differently than its book value, which is the value of UroGen that is recorded on the company's balance sheet. Investors also form their own opinion of UroGen Pharma's value that differs from its market value or its book value, called intrinsic value, which is UroGen Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UroGen Pharma's market value can be influenced by many factors that don't directly affect UroGen Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between UroGen Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if UroGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UroGen Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.